Mealey's (September 14, 2021, 2:39 PM EDT) -- NEW ORLEANS — A Fifth Circuit U.S. Court of Appeals panel on Sept. 10 affirmed a lower court’s holding that dismissed shareholder claims against a biopharmaceutical company and certain of its senior executives stemming from alleged misrepresentations the defendants made regarding the likelihood of U.S. Food and Drug Administration approval of the company’s diabetes treatment drug, ruling that investors failed to sufficiently state a claim for relief in making their federal securities law claims....